Pfizer Completes Acquisition Of Nimenrix And Mencevax From GlaxoSmithKline
October 01 2015 - 8:00AM
Business Wire
Pfizer Inc. (NYSE:PFE) today announced that it has completed the
acquisition of GlaxoSmithKline’s quadrivalent meningococcal ACWY
vaccines Nimenrix and Mencevax.
“The addition of Nimenrix and Mencevax helps us to fulfill our
vision to protect lives with innovative vaccines to fight serious
diseases worldwide,” said Susan Silbermann, president and general
manager, Pfizer Vaccines. “These vaccines add high-quality and
complementary vaccines to our existing portfolio, allowing us to
reach a broader global population.”
About Nimenrix and Mencevax
Nimenrix (meningococcal serogroups A, C, W-135 and Y conjugate
vaccine) is a single-dose meningococcal ACWY-TT (tetanus
toxoid) conjugated vaccine designed to protect against Neisseria
meningitidis, an uncommon but highly contagious disease that can
lead to disability and death. It is indicated for all age groups
above one year of age. Launched three years ago, Nimenrix is
currently registered and approved for sale in 63 countries across
the European Economic Area (EEA 30), Canada, Australia and Emerging
Markets, with registrations under review in another 17 countries
across Africa, Asia, Eastern Europe and the Middle East.
Mencevax (meningococcal polysaccharide serogroups A, C, Y and
W-135 vaccine) is a single-dose meningococcal ACWY unconjugated
polysaccharide vaccine used to control outbreaks of meningococcal
infection and for travelers in countries where the disease is
endemic or highly epidemic. Mencevax is indicated for use across
all age groups from 2 years of age, and is currently registered and
approved in 78 countries across Africa, Asia, Australia, Europe,
Latin America, Middle East and New Zealand.
About Pfizer Inc.
At Pfizer, we apply science and our global resources to bring
therapies to people that extend and significantly improve their
lives. We strive to set the standard for quality, safety and value
in the discovery, development and manufacture of health care
products. Our global portfolio includes medicines and vaccines as
well as many of the world's best-known consumer health care
products. Every day, Pfizer colleagues work across developed and
emerging markets to advance wellness, prevention, treatments and
cures that challenge the most feared diseases of our time.
Consistent with our responsibility as one of the world's premier
innovative biopharmaceutical companies, we collaborate with health
care providers, governments and local communities to support and
expand access to reliable, affordable health care around the world.
For more than 150 years, Pfizer has worked to make a difference for
all who rely on us. To learn more, please visit us at
www.pfizer.com.
DISCLOSURE NOTICE
The information contained in this release is as of October 1,
2015. Pfizer assumes no obligation to update forward-looking
statements contained in this release as the result of new
information or future events or developments.
This release contains forward-looking information about the
acquisition by Pfizer of GlaxoSmithKline’s quadrivalent
meningococcal ACWY vaccines, Nimenrix and Mencevax, and the
potential benefits thereof, that involves substantial risks and
uncertainties that could cause actual results to differ materially
from those expressed or implied by such statements. Risks and
uncertainties include, among other things, the ability to realize
the anticipated benefits of the acquisition; other business
effects, including the effects of industry, market, economic,
political or regulatory conditions; future exchange or interest
rates; the uncertainties inherent in research and development;
whether and when regulatory authorities in jurisdictions in which
applications are pending will approve such applications, which will
depend on the assessment by such regulatory authorities of the
benefit-risk profile suggested by the totality of the efficacy and
safety information submitted; decisions by regulatory authorities
regarding labeling and other matters that could affect the
availability or commercial potential of the vaccines; and
competitive developments.
A further description of risks and uncertainties can be found in
Pfizer’s Annual Report on Form 10-K for the fiscal year ended
December 31, 2014, including in the sections thereof captioned
“Risk Factors” and “Forward-Looking Information and Factors That
May Affect Future Results”, as well as in its subsequent reports on
Form 10-Q and Form 8-K, all of which are filed with the SEC and
available at www.sec.gov and www.pfizer.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151001005799/en/
PfizerMedia:Joan Campion, +1 212-733-2798+1 201-761-9384
(M)Joan.Campion@pfizer.comorInvestor:Ryan Crowe, +1 212-733-8160+1
215-260-0914 (M)Ryan.Crowe@pfizer.com
Pfizer (NYSE:PFE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pfizer (NYSE:PFE)
Historical Stock Chart
From Apr 2023 to Apr 2024